Aspect Biosystems and Novo Nordisk announce new phase of partnership to develop curative medicines for diabetes.
Aspect Biosystems and Novo Nordisk have just announced they are deepening their collaboration to accelerate advanced cellular medicines that aim to deliver functional cures for diabetes. In this new phase, Aspect will lead development, manufacturing, and commercialization while integrating select Novo Nordisk cell therapy technologies into its Canada-based platform to advance islet replacement therapies and other potentially curative treatments for serious metabolic and endocrine diseases.